A sober, sourced overview of why Peptide Sciences went dark, what it signals about the compounded-peptide market, and how to vet the suppliers stepping into…
A sober, sourced overview of why Peptide Sciences went dark, what it signals about the compounded-peptide market, and how to vet the suppliers stepping into the gap.
Peptide Sciences was, for nearly a decade, one of the most recognized names U.S. researchers reached for when ordering reference peptides. In mid-2026 the brand quietly went offline — orders stopped flowing, customer service ceased responding, and the catalog disappeared. Buyers across the research, biohacking, and wellness-professional communities began asking the same question: what actually happened, and where do we go now?
Peptide Sciences has not issued a public statement. What's verifiable is that the company's storefront, support email, and chemist-of-record pages went dark together — a pattern more consistent with an operational wind-down than a temporary outage. We're treating any unverified claim about the reasons as exactly that: unverified.
What's not in dispute is the timing. The FDA's 2024–2026 enforcement focus on compounded GLP-1s (semaglutide, tirzepatide) and on companies blurring the line between 'research use only' and human use put every major U.S. peptide supplier on notice. Several smaller brands consolidated, repositioned, or exited the U.S. market in the same window.
The shutdown clarified what really matters. A reputable U.S. peptide supplier in 2026 should be able to show you, on request:
With one of the largest players gone, the U.S. compounded-peptide market is consolidating around suppliers who treat compliance, lab transparency, and customer relationships as core product features rather than marketing copy. Expect tighter supply on niche peptides (GHK-Cu, Epitalon, MOTS-c), more stable supply on the GLP-1 class as compounders normalize their processes, and visibly higher standards on COA disclosure across the category.
Clarity Wellness is a North Carolina-based bulk-direct distributor of premium USA-compounded peptides for qualified individuals and wellness professionals. Every batch ships with a third-party Certificate of Analysis, every order ships from our U.S. compounding partner Cellular Advantage Solutions, and every member signs a written Peptide Agreement before their first order. We've operated under this model since well before the current consolidation, and we're not changing it because the market changed around us.
If you previously ordered through Peptide Sciences and want to evaluate a replacement, our catalog covers the same core research peptides — BPC-157, TB-500, GHK-Cu, the GLP-1 class (semaglutide, tirzepatide, retatrutide), the growth-hormone-support stack (CJC-1295, ipamorelin, sermorelin), NAD+, glutathione, and the longevity series (MOTS-c, epitalon). Pricing is bulk-direct and reserved for members.
The Peptide Sciences shutdown isn't the end of the U.S. compounded-peptide market — it's a forcing function. The suppliers who stay will be the ones who can show their work: COAs on every batch, U.S. compounding partners on every label, signed buyer agreements on every account. Use this moment to upgrade your supplier diligence, not to panic-buy from whichever site Google ranks first this week.
Editorial overview only. All peptide products referenced are intended solely for research, investigational, or licensed professional use. Conduct your own research and consult a trusted, licensed medical practitioner before any personal or clinical use.
| Peptide | Category | Summary |
|---|---|---|
| BPC-157 | Healing & Recovery | BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. It is among the most-studied research peptides for soft-tissue repair, tendon healing, and gastrointestinal protection — almost entirely in animal models to date. |
| Semaglutide | Metabolic & Weight | Semaglutide is a long-acting GLP-1 receptor agonist with one of the deepest clinical-trial datasets in metabolic medicine. It supports glucose-dependent insulin secretion, slows gastric emptying, and acts on central appetite pathways. |
| Tirzepatide | Metabolic & Weight | Tirzepatide is the first FDA-approved dual GIP/GLP-1 receptor agonist. By engaging two incretin pathways at once, head-to-head trials suggest larger average effects on weight and HbA1c than single-pathway GLP-1 agonists. |
| GHK-Cu | Skin, Hair & Aesthetic | GHK-Cu is a naturally occurring copper-binding tripeptide with decades of dermatological literature. Research focuses on collagen synthesis, wound healing, and hair-follicle biology. |
Published 2026-06-27 by the Clarity Wellness editorial team. Approximate reading time: 9 minutes. Our sourcing and review policy is published at /editorial-standards.
All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.